Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Clinical trial NCT05663710 · RECRUITING
Trial details
- NCT number
- NCT05663710
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-30
- Primary completion
- 2027-10-30
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.